Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Helix BioPharma has begun enrolment for the third dose level cohort and will add two centers for phase I/II study of lung cancer drug L-DOS47, in Poland.
Subscribe to our email newsletter
Three patients enrolled in the second dose level cohort completed the first treatment cycle and well tolerated the L-DOS47 therapy.
Patients to be enrolled in the third cohort will receive the next dose level 0.33 micrograms of L-DOS47 per kilogram of patient body weight.
Helix chief executive officer Robert Verhagen said, "L-DOS47 therapy continues to be well tolerated by the patients treated in our first two dose levels."
The immunoconjugate-based drug candidate, L-DOS47, is based on DOS47 technology designed to modify the microenvironmental conditions of cancer cells resulting in their destruction.